Your browser doesn't support javascript.
loading
Strategy to delay the progression of chronic kidney disease by targeting gut microbiota and uremic toxins metabolism pathway / 药学学报
Acta Pharmaceutica Sinica ; (12): 37-49, 2021.
Article in Zh | WPRIM | ID: wpr-872614
Responsible library: WPRO
ABSTRACT
Chronic kidney disease (CKD) is a serious chronic disease with high incidence, poor prognosis, and a variety of complications. Indoxyl-sulfate (IS) and p-cresol sulfate (PCS) are two typical gut-derived uremic toxins, which are produced by the co-metabolism of intestinal microbes and the host. With the progression of CKD, gut-derived uremic toxins such as IS and PCS accumulate in patients with CKD and thereafter accelerate the progression of CKD. Gut microbiota is closely related with CKD, and targeting gut microbiota to regulate gut-derived uremic toxins synthesis and metabolic pathways may be a promising strategy to delay the progression of CKD. In this paper, the relationship between gut microbiota, gut-derived uremic toxins, and CKD was analyzed, and the strategy to delay the progression of CKD by targeting gut microbiota and uremic toxins metabolism pathway was proposed.
Key words
Full text: 1 Database: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2021 Document type: Article
Full text: 1 Database: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2021 Document type: Article